{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045205","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.106942+00:00","generated_at":"2026-05-30T01:07:54.033824+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera Q3 revenue $9.0M (+1.5% YoY); net loss narrows; FDA approves higher Ameluz dosage","bullets":["Total Q3 2024 revenue $9.0M, up 1.5% YoY (would have been +19% without Hurricane Milton delays of ~$1.5M).","Net loss narrowed to $5.7M from $6.3M YoY; adjusted EBITDA -$4.6M vs -$3.9M.","FDA approved sNDA on Oct 4 to increase max Ameluz dosage from one to three tubes per treatment.","Phase 3 sBCC study met all endpoints: 75.9% histological clearance vs 19% placebo (p<0.0001); FDA filing expected H1 2025.","Cash and equivalents $2.9M at Sep 30, up from $1.3M at Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045205","json":"https://secwatch.observer/filing/0001493152-24-045205.json","markdown":"https://secwatch.observer/filing/0001493152-24-045205.md","text":"https://secwatch.observer/filing/0001493152-24-045205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224045205/0001493152-24-045205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224045205/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:07:54.033824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}